Weight-loss drugmakers Eli Lilly (LLY) and Novo Nordisk (NVO) (OTCPK:NONOF) are planning to announce new drug pricing deals ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

Patients may have trouble finding two different types of insulin products made by Eli Lilly. The company said it's experiencing a shortage of its 10 mL vials of Humalog and Insulin Lispro Injection ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

Fact checked by Jennifer Klump Key Takeaways Insulin costs have declined over the past two years, and additional price cuts ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay in manufacturing.” The ...

(The Hill) – Drugmaker Eli Lilly on Thursday warned against using its diabetes and obesity drugs for “cosmetic” weight loss, as the medications have exploded in popularity, resulting in shortages. In ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...